Fisher Asset Management LLC Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Fisher Asset Management LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 112.2% in the fourth quarter, HoldingsChannel reports. The firm owned 15,696 shares of the medical research company’s stock after buying an additional 8,298 shares during the quarter. Fisher Asset Management LLC’s holdings in IQVIA were worth $3,085,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in IQV. FMR LLC increased its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Impax Asset Management Group plc increased its position in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares during the last quarter. Nordea Investment Management AB raised its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in IQVIA by 3.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after purchasing an additional 39,772 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on IQV shares. Truist Financial restated a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Leerink Partners reiterated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Performance

Shares of IQVIA stock opened at $186.04 on Thursday. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $261.73. The company has a market capitalization of $32.80 billion, a PE ratio of 24.81, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50-day simple moving average of $198.24 and a two-hundred day simple moving average of $213.66.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.